Affordable Access

deepdyve-link
Publisher Website

[Extracorporeal shock wave therapy for Peyronie's disease].

Authors
  • Ochoa, A1
  • Guillot-Tantay, C1
  • Faix, A2
  • Misrai, V3
  • Rouprêt, M4
  • 1 Sorbonne Université, GRC 5 Predictive Onco-Uro, AP-HP, Urologie, Pitie-Salpétrière, 75013 Paris, France. , (France)
  • 2 Centre d'urologie du Polygone, les bureaux du Polygone, Montpellier, France. , (France)
  • 3 Service d'urologie, clinique Pasteur, Toulouse, France. , (France)
  • 4 Sorbonne Université, GRC 5 Predictive Onco-Uro, AP-HP, Urologie, Pitie-Salpétrière, 75013 Paris, France. Electronic address: [email protected] , (France)
Type
Published Article
Journal
Progrès en Urologie
Publisher
Elsevier
Publication Date
Sep 01, 2020
Volume
30
Issue
10
Pages
488–499
Identifiers
DOI: 10.1016/j.purol.2020.04.003
PMID: 32370921
Source
Medline
Keywords
Language
French
License
Unknown

Abstract

The efficiency of extracorporeal shock waves (SW) for Peyronie's disease (PD) is controversial. A systematic review of the literature published between 2000 and 2019 was conducted using the PRISMA methodology. We used Medline data with the following. "extracorporeal shock wave therapy" ; "Peyronie's disease"; "Sexuality"; Penile erection. Thirteen articles were selected. Our review showed that SW were beneficial in terms of pain. Regarding plaques size and penile curvature, the results remain divergent. SW may be useful in the management of pain in selected patients with PD. Its effectiveness on plaques size and penile curvature needs to be demonstrated through controlled and randomized trials. The population has to be targeted, and the treatment protocol must also be standardized. Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Report this publication

Statistics

Seen <100 times